* Acutus Medical Inc AFIB.OQ AFIB.O is expected to show a
rise in quarterly revenue when it reports results on August 12.
* The Carlsbad, California-based company is expected to report
a 283.3% increase in revenue to $4.346 million from $1.13
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Acutus Medical Inc is
for a loss of 84 cents per share. For the same quarter last
year, the company reported a loss of $32.24 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Acutus Medical
Inc is $19, about 22.5% above its last closing price
of $14.73.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.85 -0.81 -1.04 Missed -28.1
Dec. 31 2020 -0.74 -0.72 -1.05 Missed -45.4
Sep. 30 2020 -1.06 -0.99 -1.95 Missed -96.6
Jun. 30 2020 -1.03 -1.03 -32.24 Missed -3,030
.1
This summary was machine generated August 10 at 20:57 GMT. All
figures in US dollars unless otherwise stated